SCHEMBL26346649

SCHEMBL26346649

CN[C@@H](CSCC(=O)NCCOCCOCCN=[N+]=[N-])C(C)=O

nearest known ligand 0.32

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ CRBN Q96SW2 1/20 0.31
▸ TLR2 O60603 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26346640 0.85 GLP1R (0.35) MEN1KMT2ACRBN
SCHEMBL26346642 0.84 MEN1 (0.35) MEN1KMT2ACRBN
SCHEMBL26759934 0.81 ADRB2 (0.33) MEN1KMT2ACRBN
SCHEMBL25664937 0.78 ADRB2 (0.37) MEN1KMT2ATLR2
SCHEMBL26346638 0.78 GLP1R (0.40) —
SCHEMBL13695975 0.78 CRBN (0.36) MEN1KMT2ACRBN
SCHEMBL23473527 0.76 NOS3 (0.32) —
SCHEMBL12989790 0.75 MEN1 (0.35) MEN1KMT2ATLR2
SCHEMBL13695954 0.73 MEN1 (0.41) MEN1KMT2ACRBN
SCHEMBL22957224 0.73 MEN1 (0.41) MEN1KMT2ACRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303649-A1 MODIFIED IL-2 POLYPEPTIDES FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES BRIGHT PEAK THERAPEUTICS AG (CH) 2023-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303649-A1 MODIFIED IL-2 POLYPEPTIDES FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES IL2, IL2RA, ICOS MEN1 4197/4885KMT2A 1964/4885CRBN 1005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback